KBC Group NV Acquires 7,169 Shares of United Therapeutics Co. (NASDAQ:UTHR)

KBC Group NV raised its position in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 6.2% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 123,055 shares of the biotechnology company's stock after buying an additional 7,169 shares during the quarter. KBC Group NV owned about 0.28% of United Therapeutics worth $43,418,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently bought and sold shares of UTHR. Blue Trust Inc. boosted its stake in shares of United Therapeutics by 24.2% during the fourth quarter. Blue Trust Inc. now owns 1,745 shares of the biotechnology company's stock valued at $625,000 after acquiring an additional 340 shares during the last quarter. Kingswood Wealth Advisors LLC acquired a new stake in United Therapeutics during the fourth quarter worth about $225,000. Strategic Investment Advisors MI raised its stake in shares of United Therapeutics by 1.6% in the 4th quarter. Strategic Investment Advisors MI now owns 5,983 shares of the biotechnology company's stock valued at $2,111,000 after acquiring an additional 95 shares during the period. First Citizens Bank & Trust Co. boosted its position in shares of United Therapeutics by 4.3% in the fourth quarter. First Citizens Bank & Trust Co. now owns 2,796 shares of the biotechnology company's stock worth $987,000 after buying an additional 115 shares during the period. Finally, Flagship Harbor Advisors LLC lifted its position in United Therapeutics by 12.8% during the 4th quarter. Flagship Harbor Advisors LLC now owns 1,166 shares of the biotechnology company's stock worth $411,000 after acquiring an additional 132 shares in the last quarter. Institutional investors and hedge funds own 94.08% of the company's stock.

Insider Activity

In other United Therapeutics news, COO Michael Benkowitz sold 15,000 shares of the company's stock in a transaction that occurred on Thursday, November 7th. The shares were sold at an average price of $401.44, for a total value of $6,021,600.00. Following the completion of the transaction, the chief operating officer now directly owns 2,577 shares in the company, valued at approximately $1,034,510.88. This represents a 85.34 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Paul A. Mahon sold 7,700 shares of United Therapeutics stock in a transaction on Thursday, November 21st. The stock was sold at an average price of $367.36, for a total transaction of $2,828,672.00. Following the transaction, the executive vice president now directly owns 36,710 shares of the company's stock, valued at $13,485,785.60. This represents a 17.34 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 133,838 shares of company stock valued at $50,445,556. 11.90% of the stock is owned by company insiders.

United Therapeutics Price Performance

UTHR stock traded down $1.08 during midday trading on Friday, hitting $351.22. The company's stock had a trading volume of 292,541 shares, compared to its average volume of 288,431. The stock has a market capitalization of $15.68 billion, a P/E ratio of 15.42, a PEG ratio of 0.95 and a beta of 0.57. The company's fifty day moving average price is $365.47 and its 200 day moving average price is $356.78. United Therapeutics Co. has a twelve month low of $208.62 and a twelve month high of $417.82.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $6.16 by $0.23. The company had revenue of $748.90 million during the quarter, compared to analysts' expectations of $722.62 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The business's revenue was up 22.9% on a year-over-year basis. During the same period last year, the firm posted $5.38 earnings per share. Equities analysts expect that United Therapeutics Co. will post 25.22 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have recently commented on UTHR. TD Cowen increased their target price on United Therapeutics from $350.00 to $400.00 and gave the company a "buy" rating in a research note on Monday, October 21st. HC Wainwright boosted their target price on shares of United Therapeutics from $400.00 to $425.00 and gave the stock a "buy" rating in a research report on Thursday, October 31st. Oppenheimer lifted their target price on United Therapeutics from $575.00 to $600.00 and gave the stock an "outperform" rating in a research report on Thursday, October 31st. StockNews.com upgraded United Therapeutics from a "buy" rating to a "strong-buy" rating in a research note on Thursday, January 16th. Finally, Argus boosted their target price on shares of United Therapeutics from $360.00 to $400.00 and gave the company a "buy" rating in a research note on Thursday, October 31st. One analyst has rated the stock with a sell rating, two have given a hold rating, twelve have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $378.36.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.